Kurtoxin

Documents

Lys-Ile-Asp-Gly-Tyr-Pro-Val-Asp-Tyr-Trp-Asn-Cys-Lys-Arg-Ile-Cys-Trp-Tyr-Asn-Asn-Lys-Tyr-Cys-Asn-Asp-Leu-Cys-Lys-Gly-Leu-Lys-Ala-Asp-Ser-Gly-Tyr-Cys-Trp-Gly-Trp-Thr-Leu-Ser-Cys-Tyr-Cys-Gln-Gly-Leu-Pro-Asp-Asn-Ala-Arg-Ile-Lys-Arg-Ser-Gly-Arg-Cys-Arg-Ala (Disulfide bonds between Cys¹²-Cys⁶¹, Cys¹⁶-Cys³⁷, Cys²³-Cys⁴⁴, and Cys²⁷-Cys⁴⁶)
: (M.W. 7386.4) C₃₂₄H₄₇₈N₉₄O₉₀S₈
: T-type Ca²⁺ Channel Blocker

Package	Price(Yen)	Availability
Vial 0.1 mg	30,000	Ships within 1-3 business days
Bulk Request

Solubility: H₂O (50 μM)

R.S-I. Chuang, H. Jaffe, L. Cribbs, E. Perez-Reyes, and K.J. Swartz, Nat. Neurosci., 1, 668 (1998). (Original)
S.S. Sidach and I.M. Mintz, J. Neurosci., 22, 2023 (2002). (Pharmacol; Specificity for Ca2+-Channel Blocking Activity)
T. Olamendi-Portugal, B.I. García, I. López-González, J. Van DerWalt, K. Dyason, C. Ulens, J. Tytgat, R. Felix, A. Darszon, and L.D. Possani, Biochem. Biophys. Res. Commun., 299, 562 (2002). (Pharmacol.)
I. López-González, T. Olamendi-Portugal, J.L. De La Vega-Beltrán, J. Van derWalt, K. Dyason, L.D. Possani, R. Felix, and A. Darszon, Biochem. Biophys. Res. Commun., 300, 408 (2003). (Pharmacol.)
H. Nishio, Y. Nishiuchi,M. Is himaru, and T. Kimura, Lett. Pept. Sci., 10, 589 (2003). (Chem. Synthesis & S-S Bond)

Data Sheet